CN Patent

CN116514796A — 3CLpro蛋白酶抑制剂的盐、晶型及其制备方法

Assigned to Qilu Pharmaceutical Co Ltd · Expires 2023-08-01 · 3y expired

What this patent protects

本发明提供式(I)化合物(5‑溴‑2‑((R)‑1‑(5‑(甲氨基)烟碱酰)哌啶‑3‑基)氨基)‑3‑硝基苯基((2R,6S)‑2,6‑二甲基吗啉基)甲酮及其盐、晶型、制备方法和用途。

USPTO Abstract

本发明提供式(I)化合物(5‑溴‑2‑((R)‑1‑(5‑(甲氨基)烟碱酰)哌啶‑3‑基)氨基)‑3‑硝基苯基((2R,6S)‑2,6‑二甲基吗啉基)甲酮及其盐、晶型、制备方法和用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN116514796A
Jurisdiction
CN
Classification
—
Expires
2023-08-01
Drug substance claim
No
Drug product claim
No
Assignee
Qilu Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.